US Stock MarketDetailed Quotes
NRIX Nurix Therapeutics
- 22.370
- -0.270-1.19%
Close Nov 21 16:00 ET
- 23.480
- +1.110+4.96%
Post 20:01 ET
1.58BMarket Cap-7713P/E (TTM)
23.090High22.105Low729.26KVolume22.740Open22.640Pre Close16.53MTurnover1.26%Turnover RatioLossP/E (Static)70.84MShares29.56052wk High4.20P/B1.29BFloat Cap5.65052wk Low--Dividend TTM57.74MShs Float52.380Historical High--Div YieldTTM4.35%Amplitude4.220Historical Low22.661Avg Price1Lot Size
Nurix Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Aug 31, 2024 | (Q2)May 31, 2024 | (Q1)Feb 29, 2024 | (FY)Nov 30, 2023 | (Q4)Nov 30, 2023 | (Q3)Aug 31, 2023 | (Q2)May 31, 2023 | (Q1)Feb 28, 2023 | (FY)Nov 30, 2022 | (Q4)Nov 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -2.54%-42.18M | -114.98%-39.71M | 13.42%-41.95M | 49.09%-81.37M | 170.32%26.69M | 11.18%-41.13M | 43.89%-18.47M | -13.66%-48.45M | -89.42%-159.81M | -22.79%-37.96M |
| Net income from continuing operations | -32.38%-48.96M | -83.49%-44.55M | -1.93%-41.52M | 20.19%-143.95M | 10.19%-41.96M | 19.09%-36.98M | 46.53%-24.28M | 4.23%-40.73M | -53.90%-180.36M | -23.91%-46.72M |
| Operating gains losses | ---- | ---- | ---- | 6,077.78%556K | --12K | --448K | --40K | --56K | -92.97%9K | --0 |
| Depreciation and amortization | 22.52%4.15M | 22.74%4.09M | 22.26%3.89M | 26.33%13.65M | 23.71%3.76M | 17.26%3.38M | 26.63%3.33M | 41.15%3.18M | 77.70%10.81M | 88.63%3.04M |
| Other non cash items | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --201K | --0 |
| Change In working capital | 81.73%-2.7M | -12.04%-5.94M | 45.14%-10.21M | 205.78%20.12M | 3,160.35%58.82M | -40.04%-14.78M | -319.02%-5.3M | -107.72%-18.62M | -308.73%-19.02M | -617.16%-1.92M |
| -Change in receivables | ---- | ---- | ---- | --0 | --2M | ---- | ---- | ---- | 354.45%6M | --0 |
| -Change in prepaid assets | -127.93%-570K | -92.11%169K | 171.79%1.17M | 295.52%2.14M | -136.07%-417K | 377.69%2.04M | 214,300.00%2.14M | -7.46%-1.63M | 79.90%-1.09M | 93.31%1.16M |
| -Change in payables and accrued expense | 103.92%7.13M | -49,468.42%-9.38M | 140.94%2.66M | -37.42%4.74M | 222.28%7.73M | 481.06%3.5M | -99.76%19K | -90.15%-6.51M | -3.04%7.57M | -43.51%2.4M |
| -Change in other current liabilities | 9.70%-1.68M | 8.31%-1.63M | -11.98%-1.46M | -28.68%-6.27M | -11.41%-1.33M | -64.10%-1.86M | 16.73%-1.78M | -219.12%-1.3M | 5.31%-4.87M | 56.05%-1.19M |
| -Change in other working capital | 53.92%-7.59M | 186.47%4.91M | -37.04%-12.59M | 173.28%19.51M | 1,287.02%50.84M | -77.21%-16.47M | 39.81%-5.68M | -153.70%-9.18M | -286.86%-26.63M | -218.87%-4.28M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -2.54%-42.18M | -114.98%-39.71M | 13.42%-41.95M | 49.09%-81.37M | 170.32%26.69M | 11.18%-41.13M | 43.89%-18.47M | -13.66%-48.45M | -89.42%-159.81M | -22.79%-37.96M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -193.69%-21.34M | -399.03%-131.07M | 121.02%35.51M | 151.13%68.3M | -126.13%-14.37M | 136.11%22.78M | 1,019.85%43.83M | -59.86%16.07M | 125.12%27.2M | 250.61%55.01M |
| Net PPE purchase and sale | 4.55%-2.35M | -79.35%-1.94M | -26.66%-2.88M | 31.39%-8.4M | -0.78%-2.59M | 28.06%-2.46M | 61.28%-1.08M | 34.42%-2.28M | -116.29%-12.24M | -197.56%-2.57M |
| Net investment purchase and sale | -175.26%-18.99M | -387.53%-129.13M | 109.30%38.4M | 94.47%76.7M | -120.47%-11.79M | 142.30%25.23M | 2,372.82%44.91M | -57.83%18.35M | 138.45%39.44M | 261.45%57.57M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -193.69%-21.34M | -399.03%-131.07M | 121.02%35.51M | 151.13%68.3M | -126.13%-14.37M | 136.11%22.78M | 1,019.85%43.83M | -59.86%16.07M | 125.12%27.2M | 250.61%55.01M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 2,586.03%45.77M | 950,908.00%237.75M | 9.66%1.62M | -97.25%3.22M | 105.19%7K | -98.52%1.7M | -94.21%25K | -0.47%1.48M | -23.84%117.19M | -127.00%-135K |
| Net common stock issuance | --41.87M | ---- | ---- | --0 | --0 | --0 | ---- | ---- | -87.08%19.4M | --0 |
| Proceeds from stock option exercised by employees | 128.76%3.9M | 704.00%201K | 9.66%1.62M | -96.71%3.22M | 105.19%7K | -98.23%1.7M | -94.21%25K | -0.47%1.48M | 2,525.29%97.79M | -127.00%-135K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 2,586.03%45.77M | 950,908.00%237.75M | 9.66%1.62M | -97.25%3.22M | 105.19%7K | -98.52%1.7M | -94.21%25K | -0.47%1.48M | -23.84%117.19M | -127.00%-135K |
| Net cash flow | ||||||||||
| Beginning cash position | 96.61%117.69M | 47.12%50.71M | -15.06%55.53M | -19.08%65.38M | -10.84%43.21M | 41.06%59.86M | -56.74%34.47M | -19.08%65.38M | -32.41%80.79M | -67.20%48.46M |
| Current changes in cash | -6.56%-17.75M | 163.82%66.98M | 84.42%-4.81M | 36.13%-9.85M | -27.16%12.32M | -376.51%-16.65M | 168.16%25.39M | -2,681.55%-30.9M | 60.20%-15.42M | 125.28%16.92M |
| End cash Position | 131.33%99.95M | 96.61%117.69M | 47.12%50.71M | -15.06%55.53M | -15.06%55.53M | -10.84%43.21M | 41.06%59.86M | -56.74%34.47M | -19.08%65.38M | -19.08%65.38M |
| Free cash flow | -2.14%-44.52M | -113.01%-41.64M | 11.62%-44.84M | 47.83%-89.77M | 159.49%24.1M | 12.34%-43.59M | 45.25%-19.55M | -10.04%-50.73M | -91.11%-172.05M | -27.53%-40.52M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data